Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL...

Details Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL... Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL...

2011-03-22

2011-03-22

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S330000, C544S331000

Reexamination Certificate

active

07910598

ABSTRACT:
The present invention relates to novel intermediates useful for the preparation of novel phenylaminopyrimidine derivatives, novel phenylaminopyrimidine derivatives. Pharmaceutical composition containing the novel phenylaminopyrimidine derivatives and processes for their preparation. The invention particularly relates to novel Phenyl pyrimidine amine derivatives of the general formula (I). The novel compounds of the formula 1 can be used in the therapy of Chronic Myeloid Leukemia (CML). Since the IC50; 191 values of these molecules are in the range 0.1 to 10.0 nm, these novel compounds are potentially useful for the treatment of CML.

REFERENCES:
patent: 0 564 409 (1993-10-01), None
patent: WO 95/09847 (1995-04-01), None
patent: WO 99/15164 (1999-04-01), None
patent: WO 02/22597 (2002-03-01), None
patent: WO 2004/029038 (2004-04-01), None
patent: WO 2004/110452 (2004-12-01), None
patent: WO 2006/027795 (2006-03-01), None
patent: WO 2008/058037 (2008-05-01), None
Okram et al., A General Strategy for Creating “Inactive-Conformation” Abl Inhibitiors, Chemistry & Biology, 13(7), pp. 779-786 (Jul. 2006).
Okram et al., Supplemental Data: A General Strategy for Creating “Inactive-Conformation” Abl Inhibitiors, Chemistry & Biology, 13(7), pp. 1-24 (Jul. 2006).
Ogata et al. “Synthesis and Antiviral activity of sulphonamidobenzophenone oximes and sulphonamidobenzamides.”Journal of Medicinal Chemistry. vol. 29, No. 3. 1986. pp. 417-423.
Zimmermann et al. “Potent and selective inhibitors of the Abl-kinase: Phenylaminopyrimidine (PAP) derivatives.”Bioorganic and Medicinal Chemistry Letters. vol. 7, No. 2. 1997. pp. 187-192.
Schindler et al. “Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase.”Science. vol. 289, No. 5486. 2000. pp. 1938-1942.
Invitation to Pay Additional Fees with Partial International Search mailed Jul. 15, 2009.
Examination Report from corresponding European Application No. 05 779 775.5-2101 dated Feb. 16, 2010.
Examination Report from corresponding European Application No. 05 779 775.5-2101 dated Apr. 25, 2008.

Affiliated with

Also associated with

Rating

Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2626593